{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:50:43Z","timestamp":1758970243687,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.10231.BD (DOCTORATES 4 COVID-19)"],"award-info":[{"award-number":["2020.10231.BD (DOCTORATES 4 COVID-19)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11096-021-01289-0","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T11:07:11Z","timestamp":1622632031000},"page":"1133-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-6021","authenticated-orcid":false,"given":"Renato","family":"Ferreira-da-Silva","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8158","authenticated-orcid":false,"given":"In\u00eas","family":"Ribeiro-Vaz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-0613","authenticated-orcid":false,"given":"Manuela","family":"Morato","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-7217","authenticated-orcid":false,"given":"Jorge Junqueira","family":"Pol\u00f3nia","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"4","key":"1289_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.1866","volume":"108","author":"J Sun","year":"2020","unstructured":"Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther. 2020;108(4):791\u20137. https:\/\/doi.org\/10.1002\/cpt.1866.","journal-title":"Clin Pharmacol Ther"},{"key":"1289_CR2","doi-asserted-by":"publisher","unstructured":"Senanayake SL. Drug repurposing strategies for COVID-19. Future Drug Discov. 2020;2(2). doi: https:\/\/doi.org\/10.4155\/fdd-2020-0010.","DOI":"10.4155\/fdd-2020-0010"},{"issue":"19","key":"1289_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2001282.","journal-title":"N Engl J Med"},{"issue":"10238","key":"1289_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/s0140-6736(20)31042-4","volume":"395","author":"IF Hung","year":"2020","unstructured":"Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695\u2013704. https:\/\/doi.org\/10.1016\/s0140-6736(20)31042-4.","journal-title":"Lancet"},{"issue":"5","key":"1289_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","volume":"46","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854\u201387. https:\/\/doi.org\/10.1007\/s00134-020-06022-5.","journal-title":"Intensive Care Med"},{"key":"1289_CR6","unstructured":"Low-Cost Dexamethasone Reduces Death By Up To One Third In Hospitalised Patients With Severe Respiratory Complications Of COVID-19 - RECOVERY Trial. https:\/\/www.recoverytrial.net\/news\/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19 (2020). Accessed February 20 2021."},{"issue":"3","key":"1289_CR7","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/bcp.14459","volume":"87","author":"M Gatti","year":"2021","unstructured":"Gatti M, Fusaroli M, Caraceni P, Poluzzi E, De Ponti F, Raschi E. Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2021;87(3):1533\u201340. https:\/\/doi.org\/10.1111\/bcp.14459.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1289_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5582\/bst.2020.03082","volume":"14","author":"K Sato","year":"2020","unstructured":"Sato K, Mano T, Iwata A, Toda T. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends. 2020;14(2):139\u201343. https:\/\/doi.org\/10.5582\/bst.2020.03082.","journal-title":"Biosci Trends"},{"key":"1289_CR9","unstructured":"Agency EM: EMA and ECDC join forces for enhanced post-marketing monitoring of COVID-19 vaccines in Europe. https:\/\/www.ema.europa.eu\/en\/news\/ema-ecdc-join-forces-enhanced-post-marketing-monitoring-covid-19-vaccines-europe (2021). Accessed April 30 2021."},{"key":"1289_CR10","unstructured":"Food and Drug Administration US: COVID-19 Vaccine Safety Surveillance. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/covid-19-vaccine-safety-surveillance (2021). Accessed April 30 2021."},{"issue":"13","key":"1289_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.20344\/amp.15375","volume":"34","author":"R Ferreira-da-Silva","year":"2021","unstructured":"Ferreira-da-Silva R, Ribeiro-Vaz I, Morato M, Silva AM, Junqueira PJ. The Role of Pharmacovigilance in the COVID-19 Pandemic. Acta Med Port. 2021;34(13):173\u20135. https:\/\/doi.org\/10.20344\/amp.15375.","journal-title":"Acta Med Port"},{"issue":"4","key":"1289_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11096-018-0689-6","volume":"40","author":"P In\u00e1cio","year":"2018","unstructured":"In\u00e1cio P, Cavaco A, Airaksinen M. Current trends in pharmacovigilance: value and gaps of patient reporting. Int J Clin Pharm. 2018;40(4):754\u20137. https:\/\/doi.org\/10.1007\/s11096-018-0689-6.","journal-title":"Int J Clin Pharm"},{"key":"1289_CR13","unstructured":"(VAC4EU) VmCfE: Cohort Event Monitoring of safety of COVID-19 vaccines (EUPAS39798). http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=40288 (2021). Accessed May 24 2021."},{"issue":"7","key":"1289_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40264-014-0180-9","volume":"37","author":"H Pontes","year":"2014","unstructured":"Pontes H, Cl\u00e9ment M, Rollason V. Safety signal detection: the relevance of literature review. Drug Saf. 2014;37(7):471\u20139. https:\/\/doi.org\/10.1007\/s40264-014-0180-9.","journal-title":"Drug Saf"},{"issue":"6","key":"1289_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","volume":"16","author":"RH Meyboom","year":"1997","unstructured":"Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16(6):355\u201365. https:\/\/doi.org\/10.2165\/00002018-199716060-00002.","journal-title":"Drug Saf"},{"issue":"6","key":"1289_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jamia\/ocx102","volume":"25","author":"OO Agoro","year":"2017","unstructured":"Agoro OO, Kibira SW, Freeman JV, Fraser HSF. Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation. J Am Med Inform Assoc. 2017;25(6):627\u201334. https:\/\/doi.org\/10.1093\/jamia\/ocx102.","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"1289_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrg3208","volume":"13","author":"PB Jensen","year":"2012","unstructured":"Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13(6):395\u2013405. https:\/\/doi.org\/10.1038\/nrg3208.","journal-title":"Nat Rev Genet"},{"key":"1289_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.artmed.2018.07.005","volume":"91","author":"PP Rodrigues","year":"2018","unstructured":"Rodrigues PP, Ferreira-Santos D, Silva A, Polonia J, Ribeiro-Vaz I. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network. Artif Intell Med. 2018;91:12\u201322. https:\/\/doi.org\/10.1016\/j.artmed.2018.07.005.","journal-title":"Artif Intell Med"},{"issue":"2","key":"1289_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-020-00999-0","volume":"44","author":"K Chinchilla","year":"2021","unstructured":"Chinchilla K, Matos C, Hall V, van Hunsel F. Patient Organizations\u2019 Barriers in Pharmacovigilance and Strategies to Stimulate Their Participation. Drug Saf. 2021;44(2):181\u201391. https:\/\/doi.org\/10.1007\/s40264-020-00999-0.","journal-title":"Drug Saf"},{"issue":"8","key":"1289_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40264-020-00965-w","volume":"43","author":"M Tuccori","year":"2020","unstructured":"Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The Impact of the COVID-19 \u201cInfodemic\u201d on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020;43(8):699\u2013709. https:\/\/doi.org\/10.1007\/s40264-020-00965-w.","journal-title":"Drug Saf"},{"key":"1289_CR21","unstructured":"Agency EM: List of medicines under additional monitoring. https:\/\/www.ema.europa.eu\/en\/documents\/additional-monitoring\/list-medicinal-products-under-additional-monitoring_en-0.pdf (2021). Accessed May 23 2021."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-021-01289-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:31:43Z","timestamp":1628537503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-021-01289-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s11096-021-01289-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}